How should I adjust my filler strategy for patients on GLP-1 medications?
According to new global consensus guidance, providers should prioritize biostimulatory injectables (like PLLA or CaHA) for structural support rather than relying solely on HA fillers. Radiographic data from a separate study suggests anticipating approximately 7% midfacial volume loss for every 10 kg of body weight lost, so plan staged restoration as the patient’s weight stabilizes.
What is the clinical evidence supporting polynucleotides (PDRN)?
Recent data published in BMJ Open indicates that polynucleotides can increase collagen production by up to approximately 47% within 23 days in a specific treatment protocol. They work by stimulating fibroblast proliferation and extracellular matrix synthesis.
Are injectable exosomes FDA-approved for aesthetic use?
As of early 2026, no exosome product is FDA-approved for injection. While studies show efficacy in collagen remodeling, compliant clinical application remains strictly limited to topical use post-procedure, such as following microneedling.
How does treating male patients differ from treating female patients with neurotoxins?
Male facial anatomy typically features greater muscle mass, which often requires approximately 20 to 30 percent higher dosing than comparable female patients to achieve the desired effect. Injection patterns must also be individualized to maintain a masculine brow position and avoid feminization.
What is the current status of compounded injectable peptides like BPC-157?
Category 2 peptides, including BPC-157, remain on the FDA’s do-not-compound list under current guidance. While there is ongoing advocacy pressure suggesting a potential policy review, providers should not change clinical practice until an official reclassification is published in the Federal Register.
